drugset / Trial / NCT02063997

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

NCT02063997

Phase 2 Completed 248 enrolled Gilead Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.

Timeline

Start
2014-03
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 300 mg
Subject Arhalofenate Unknown 600 mg
Subject Arhalofenate Unknown 800 mg
Comparator Colchicine Small molecule 0.6 mg

Indications